Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
Nuvectis Pharma (NASDAQ: NVCT), a clinical-stage biopharmaceutical company specializing in innovative precision medicines for oncology, has announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference. The event is scheduled for October 9, 2024, in New York, NY.
Nuvectis management will take part in a panel discussion focused on 'Innovative Therapies for Solid Tumors'. This panel is set to begin at 12:30 pm ET on the day of the conference.
The company's involvement in this prestigious healthcare conference underscores its commitment to advancing treatments for serious conditions with unmet medical needs in oncology, particularly in the realm of solid tumors.
Nuvectis Pharma (NASDAQ: NVCT), una società biofarmaceutica in fase clinica specializzata in medicinali innovativi di precisione per l'oncologia, ha annunciato la sua partecipazione alla 3ª Conferenza Annuale sulle Opportunità Sanitarie ROTH. L'evento è programmato per il 9 ottobre 2024 a New York, NY.
La direzione di Nuvectis parteciperà a una discussione panel incentrata su 'Terapie Innovative per Tumori Solidi'. Questo panel inizierà alle 12:30 ET nel giorno della conferenza.
Il coinvolgimento dell'azienda in questa prestigiosa conferenza sanitaria sottolinea il suo impegno a promuovere trattamenti per condizioni gravi con esigenze mediche non soddisfatte nell'oncologia, in particolare nel campo dei tumori solidi.
Nuvectis Pharma (NASDAQ: NVCT), una empresa biofarmacéutica en etapa clínica especializada en medicamentos innovadores de precisión para la oncología, ha anunciado su participación en la 3ª Conferencia Anual de Oportunidades en Salud ROTH. El evento está programado para el 9 de octubre de 2024 en Nueva York, NY.
La gerencia de Nuvectis participará en una mesa redonda centrada en 'Terapias Innovadoras para Tumores Sólidos'. Esta mesa redonda comenzará a las 12:30 pm ET el día de la conferencia.
La participación de la empresa en esta prestigiosa conferencia de salud subraya su compromiso con el avance de tratamientos para condiciones graves con necesidades médicas no satisfechas en oncología, particularmente en el ámbito de los tumores sólidos.
누벡티스 제약 (NASDAQ: NVCT)는 온콜로지에 대한 혁신적인 정밀 의약품을 전문으로 하는 임상 단계의 생명공학 회사로, 제3회 연례 롯 헬스케어 기회 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 10월 9일에 뉴욕에서 열릴 예정입니다.
누벡티스 경영진은 '고형 종양을 위한 혁신적인 치료법'에 초점을 맞춘 패널 토론에 참가할 것입니다. 이 패널은 컨퍼런스 당일 오후 12:30 ET에 시작될 예정입니다.
이 회사가 이 권위 있는 헬스케어 컨퍼런스에 참여하는 것은 온콜로지 분야에서 심각한 질병의 치료법을 발전시키려는 의지를 강조합니다. 특히 고형 종양 분야에서 그러합니다.
Nuvectis Pharma (NASDAQ: NVCT), une société biopharmaceutique en phase clinique spécialisée dans les médicaments de précision innovants pour l'oncologie, a annoncé sa participation à la 3ème Conférence Annuelle des Opportunités de Santé ROTH. L'événement est prévu pour le 9 octobre 2024 à New York, NY.
La direction de Nuvectis participera à une discussion en panel axée sur 'Thérapies Innovantes pour les Tumeurs Solides'. Ce panel débutera à 12h30 ET le jour de la conférence.
La participation de l'entreprise à cette prestigieuse conférence sur la santé souligne son engagement à faire avancer les traitements pour des conditions graves ayant des besoins médicaux non satisfaits en oncologie, en particulier dans le domaine des tumeurs solides.
Nuvectis Pharma (NASDAQ: NVCT), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf innovativen Präzisionsmedikamente für die Onkologie spezialisiert hat, hat seine Teilnahme an der 3. jährlichen ROTH Healthcare Opportunities Conference angekündigt. Die Veranstaltung ist für den 9. Oktober 2024 in New York, NY, geplant.
Das Management von Nuvectis wird an einer Podiumsdiskussion teilnehmen, die sich auf 'Innovative Therapien für solide Tumoren' konzentriert. Diese Diskussion beginnt am Konferenztag um 12:30 Uhr ET.
Das Engagement des Unternehmens in dieser prestigeträchtigen Gesundheitskonferenz unterstreicht sein Engagement für die Weiterentwicklung von Behandlungen für schwerwiegende Erkrankungen mit unerfülltem medizinischem Bedarf in der Onkologie, insbesondere im Bereich der soliden Tumoren.
- None.
- None.
Fort Lee, NJ , Oct. 07, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that management will participate in a panel discussion on innovative therapies for solid tumors at the 3rd Annual ROTH Healthcare Opportunities Conference taking place on October 9, 2024 in New York, NY.
| Event | Annual ROTH Healthcare Opportunities Conference |
| Panel Title | Innovative Therapies for Solid Tumors |
| Date and Time | October 9, 2024, 12:30 pm ET |
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two clinical-stage drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. The U.S. Food and Drug Administration granted Fast Track Designation to the NXP800 development program in platinum resistant, ARID1a-mutated ovarian carcinoma, and Orphan Drug Designation for the treatment of cholangiocarcinoma and ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900 has a unique mechanism of action in that it inhibits both the catalytic and scaffolding functions of the SRC kinase thereby providing complete shutdown of the signaling pathway. NXP900 is currently in a Phase 1a dose escalation study.
Company Contact
Ron Bentsur
Chairman, Chief Executive Officer and President
201-614-3151
rbentsur@nuvectis.com
Media Relations Contact
Christopher M. Calabrese
LifeSci Advisors
Tel: 917-680-5608
ccalabrese@lifesciadvisors.com
FAQ
When is Nuvectis Pharma (NVCT) participating in the ROTH Healthcare Opportunities Conference?
What panel is Nuvectis Pharma (NVCT) participating in at the ROTH conference?
What time is Nuvectis Pharma's (NVCT) panel discussion at the ROTH conference?
What is the focus of Nuvectis Pharma's (NVCT) research and development?
